-
Turning waste into treasure! Ineffective for Alzheimer's disease but may be used to treat cancer
Time of Update: 2021-12-01
BACE1 inhibitors used to be potential drugs for the treatment of Alzheimer's disease, and the scientific community has also expressed great expectations for it .
Therefore, researchers have speculated that inhibiting the function of BACE1 can reduce amyloid plaques, which can be used to treat Alzheimer's disease .
-
Will dyeing hair cause cancer? More and more studies have found that the risk of these cancers will increase
Time of Update: 2021-12-01
After removing the influence of other factors, the results of the study showed that compared with women who did not use hair dye, women who used permanent hair dye within 1 year had a 9% higher risk of breast cancer .
-
Refresh cognition... Cancer cells will actively attack immune cells and steal each other’s mitochondria
Time of Update: 2021-12-01
The new study found that when cancer cells and immune cells coexist, the former will stretch out extremely tiny "tentacles" to steal substances necessary for survival from neighbors .
Note: The original text has been deletedReference materials:[1] Cancer cells use'tiny tentacles' to suppress the immune system.
-
Significantly reduce blood lipids, innovative antisense oligonucleotide therapy reaches phase 2b clinical endpoint
Time of Update: 2021-12-01
On November 24, 2021, Ionis pharmaceuticals announced that vupanorsen, jointly developed with Pfizer, has reached primary and critical secondary clinical endpoints in phase 2b clinical trials .
-
Turning the complex into simple AI images show their talents in disease diagnosis and treatment
Time of Update: 2021-12-01
Wang Zhiqun mentioned that for patients with ischemic stroke, AI images can be used to diagnose the type of cerebral infarction and hemorrhage, improve the efficiency of diagnosis and treatment, and reduce artificial errors .
-
Fauci: It will take two weeks to learn the exact information about the Omi Keron strain
Time of Update: 2021-12-01
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the 28th that it would take about two weeks to obtain complete data on the Omi Keron strain of the new coronavirus mutant .
-
Bristol-Myers Squibb announces the latest progress in protein degradation therapy and cancer immunotherapy
Time of Update: 2021-12-01
▲The mechanism of CELMoD degrading Ikaros/Aiolos protein (picture source: Bristol-Myers Squibb official website)Iberdomide, developed based on this platform, combined with other standard treatment drugs for multiple myeloma, has shown good anti-cancer activity in clinical trials for multiple myeloma patients who have received a variety of pre-treatments .
-
Reduce the bleeding rate of patients with hemophilia by about 90%. One-shot RNAi therapy per month reaches the phase 3 clinical endpoint
Time of Update: 2021-12-01
The latest abstract of the ASH annual meeting showed that in patients who do not express inhibitors that inhibit exogenous coagulation factors in the body, a monthly dose of fitusiran significantly reduces the annual bleeding rate (ABR) of patients compared with receiving concentrated coagulation factors on demand.
-
Artificial intelligence technology reveals previously unknown cellular components
Time of Update: 2021-12-01
Researchers from the University of California San Diego School of Medicine and their collaborators introduced the scale-integrated cell (MuSIC) technology in a paper published in the journal Nature on the 24th, which is a combination of microscopy, biochemistry and artificial Intelligent technology reveals previously unknown cellular components and provides new clues for human development and diseases .
-
my country's new crown specific drug "candidate seeds" Phase III clinical unblind
Time of Update: 2021-12-01
One step ahead, the team, with its rich experience in the development of antiviral drugs, evaluated the neutralizing activity of its candidate antibody combination BRII-196/BRII-198 against mutant strains in the early stages of clinical trials, effectively avoiding being "on the battlefield" but being infected by the virus.
-
100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive
Time of Update: 2021-12-01
On November 22, 2021, Affimed announced that its umbilical cord blood-derived natural killer cell therapy will be combined with the innate cell engager (ICE) AFM13 in advance to treat Hodgkins and patients who have received multi-line pre-treatment.
-
Why do people sleep?
Time of Update: 2021-12-01
According to a new study published in "Molecular Cell" on November 18, researchers from Bar-Ilan University in Israel found that the PARP1 protein in the brain is like an "antenna" that can send time signals to the brain to sleep and repair DNA damage.
-
Nature's latest achievement: IL-27, a new target for immunotherapy for obesity
Time of Update: 2021-12-01
This study found for the first time the protective effect of IL-27 signaling pathway in metabolic diseases, and for the first time proved that IL-27 receptor (IL-27Ra, or WSX-1) is expressed on non-immune cells-adipocytes And play an important function .
-
New drugs for prostate cancer are 80% effective
Time of Update: 2021-12-01
Innovation Connection RussiaThe Russian National Research University "Moscow State Institute of Steel and Alloys" announced that a team of scientists from Russia's leading universities has developed drugs for the treatment of prostate cancer with a treatment efficiency of 80% .
-
The first! Takeda's antiviral therapy Livtencity receives FDA approval
Time of Update: 2021-12-01
S. FDA announced that it has approved Takeda’s development of the antiviral therapy Livtencity (maribavir) for the treatment of refractory adults or children over 12 years of age after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT).
-
Early stages of human development can be "perspected"
Time of Update: 2021-12-01
People's current understanding of the formation of human gastrulation is basically limited to experimental models, and it is impossible to directly conduct research on it, because human embryos at this stage are difficult to obtain.
-
One-time gene therapy receives FDA priority review qualification for the treatment of beta thalassemia
Time of Update: 2021-12-01
S. FDA has granted priority review qualifications for the biologics license application (BLA) for gene therapy betibeglogene autotemcel (beti-cel) for the treatment of beta cells that require routine red blood cell transfusion Patients with thalassemia .
-
The anti-cancer magic weapon hidden in the desert may solve chemotherapy resistance
Time of Update: 2021-12-01
According to a study published in Biomolecules by Professor Stark and colleagues, they isolated a substance called flavonoids from these plants, which has the effect of inhibiting the efflux pump function .
-
Meituan enters the medical surgical robot
Time of Update: 2021-12-01
Connaught's current round of financing is mainly used for surgical robot product research and development, clinical trials, market promotion, new product layout and industry-leading technology platform construction .
-
mRNA cancer vaccine obtains FDA fast track qualification to treat melanoma
Time of Update: 2021-12-01
“The FDA’s grant of Fast Track status underscores the potential of our FixVac platform, which is expected to solve the current treatment challenges faced by melanoma patients .
"Reference materials:Reference materials:[1] BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma.
Retrieved November 19, 2021, from https:// /BioNTech-Receives-FDA-Fast-Track-Designation-for-its-FixVac-Candidate-BNT111-in-Advanced-Melanoma.
